Measuring Competence? Exploring Firm Effects in Pharmaceutical Research

Strategic Management Journal

Volumn 15, Issue 1 S, 1994, Pages 63-84

  Henderson, Rebecca ^a   Cockburn, Iain ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Firm effects; organizational competence; pharmaceutical research productivity; resource based view

Indexed keywords

EID: 84989085903     PISSN: 01432095     EISSN: 10970266     Source Type: Journal    
DOI: 10.1002/smj.4250150906     Document Type: Article

References (60)

1. R&D performance as a function of internal communication, project management and the nature of work
2. Strategic assets and organizational rent
3. Strategy factor market: Expectation, luck and business strategy
4. Firm resources and sustained competitive advantage
5. Fading memories: A process study of strategic business exit in dynamic environments
6. Exploring the limits of the technology S‐curve, Parts I and II
7. Industry effects and appropriability measures in the stock market's valuation of R&D and patents
8. Racing to invest? The dynamics of competition in ethical drug discovery
9. Performance differences among strategic group members
10. Asset stock accumulation and sustainability of competitive advantage
11. Pseudo‐maximum likelihood methods: Applications to Poisson models
12. A new look at the returns and risks to pharmaceutical R&D
13. Determinants of firm performance: The relative importance of economic and organizational factors
14. Econometric models for count data with an application to the patents‐R&D relationship
15. Underinvestment and incompetence as responses to radical innovation: Evidence from the semiconductor photolithographic alignment equipment industry
16. The evolution of integrative capability: Innovation in cardiovascular drug discovery
17. Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms
18. Organizational effectiveness and the institutional environment
19. Corporate distinctive competence, strategy, industry and performance
20. Agency costs and innovation
21. Technological opportunity and spillovers of R&D: Evidence from firms' patents, profits and market value
22. A bibliometric analysis of pharmaceutical research
23. Knowledge of the firm, combinative capabilities, and the replication of technology
24. Core capabilities and core rigidities: A paradox in managing new product development
25. Uncertain imitability: An analysis of interfirm difference in efficiency under competition
26. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase
27. Whether and when? Probability and timing of incumbent's entry into emerging industrial subfields
28. Are more good things better: Or will technical and market capabilities conflict when a firm expands?
29. Diversification, Ricardian rents, and Tobin's q
30. Why do firms differ and how does it matter?
31. The cornerstones of competitive advantage: A resource‐based view
32. The process of technology transfer to the new biomedical and pharmaceutical firm
33. How much does industry matter?
34. Success rates in the U.S. drug development system
35. A resource‐based view of the firm
36. Country patterns in R&D organization: The United States and Japan